RCS - Oxford BioDynamics - OBD opens UK clinical testing facility

Oxford BiodynamicsAnnouncement

03/04/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240403:nRSC0552Ja&default-theme=true

RNS Number : 0552J  Oxford BioDynamics PLC  03 April 2024

 

 

Oxford Biodynamics opens clinical testing facility in the UK

to perform EpiSwitch® Prostate Screening (PSE) blood test

·    OBD commissions an ISO15189 clinical laboratory in its UK facility

·    Clinical validation completed in OBD's clinical laboratory enabling
immediate application of the EpiSwitch Prostate Screening (PSE) test

·    Expands OBD's testing capacity and significantly shortens the
turnaround time for tests ordered in the UK

·    PSE provides a high accuracy second opinion for men receiving an
accelerating or elevated PSA score

Oxford, UK - 3 April 2024 - Oxford BioDynamics, Plc (AIM: OBD, the Company), a
biotechnology company developing precision medicine tests based on the
EpiSwitch® 3D genomics platform, announces the completion of the clinical
validation of its EpiSwitch Prostate Screening (PSE) test at the Company's
newly commissioned ISO15189 UK clinical laboratory.

The launch of the 94% accurate(1) precision medicine testing in the UK will
cut in half the turnaround time for any PSE tests ordered by UK physicians.
The test has been available in the UK since September 2023 but until now all
samples were sent to OBD's US CLIA-certified lab for analysis and reporting
prior to the opening of this UK-based clinical facility.

"The commissioning of a new clinical lab and the validation of PSE testing
within that laboratory is an important milestone for the company" said Thomas
Guiel, Chief Operating Officer. "The immediate benefit for our clients in the
UK will be the significant reduction in the elapsed time from receipt of an
order to result, which will now be 5 days or less.  We are continually
seeking to expand our markets and user base; having 2 labs will be necessary
as demand grows for the PSE test."

EpiSwitch Prostate Screening test (PSE)

The PSE test combines the PSA score with five proprietary epigenetic
biomarkers to predict, with 94% accuracy, the presence (or absence) of
prostate cancer.(1) Those with a PSE result of low likelihood of cancer can be
placed on active surveillance and retested later without being referred for an
invasive and often destructive biopsy. A high likelihood result would
necessitate referral to a Urologist for further investigation.  This
minimally invasive blood test is designed to be run alongside a standard PSA
test to boost PSA's low sensitivity (64%) and low positive predictive value
(25%).(2) For each patient, the EpiSwitch technology captures personal
epigenetic biomarkers that represent a systemic fingerprint of specific
regulatory network changes associated with prostate cancer.(1)

Patients should speak to their doctor about ordering the PSE test
(www.94percent.com).  Their doctor will submit a test requisition and arrange
for a small sample of the patient's blood to be collected.  Test results will
be returned to the ordering physician within five days after the blood sample
is received in the laboratory.

Please contact Oxford BioDynamics client services anytime by emailing the team
at pse.test@myobdx.com. More information may be found at www.94percent.com
(https://url.avanan.click/v2/___http:/www.94percent.com___.YXAxZTpzaG9yZWNhcDphOm86YTMzMmU2OTkwMjUxOWJiMDZjOGY4ODI0MmZiYjQ0MzE6Njo4YjE5OjM2M2Q0ZmM3NzA0OTgxMjFiNTUzNDYyY2VjOTQwMDUwZjE3MzAzNDY2ZjlmZjhlMTY3MWU5ZjFlMjVjZmFiN2Y6cDpU)
.

 

Validation for other EpiSwitch tests, including CiRT

OBD will soon begin validating its other marketed precision medicine clinical
test, the EpiSwitch Checkpoint Inhibitor Response Test (CiRT) (www.mycirt.com)
within this new UK facility.  The CiRT test is currently available in the UK,
but testing is performed in OBD's US CLIA-certified facility.  The validation
of CiRT will be completed over the coming months which will be an important
advance for OBD's partners and customers in the UK, including its strategic
partner, Bupa UK.

-Ends-

Proof Sources

1.    "Circulating Chromosome Conformation Signatures Significantly Enhance
PSA Positive Predicting Value and Overall Accuracy for Prostate Cancer
Detection". Cancers. 2023; 15(3):821. Pchejetski D, Hunter E, Dezfouli M, et
al.

2.    "Should I have a PSA test?" National Health System - United
Kingdom.  https://www.nhs.uk/conditions/prostate-cancer/ "Diagnostic accuracy
of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired
validating confirmatory study". Lancet. Ahmed, Bosaily, Brown, et al.

 

For more information:

 

 Oxford BioDynamics Plc                                Tel: +44 (0)1865 518910

 Jon Burrows, CEO

 Paul Stockdale, CFO

 Shore Capital - Nominated Adviser                     Tel: +44 (0)20 7408 4090

 Advisory: Stephane Auton / Iain Sexton

 Broking: Fiona Conroy

 Instinctif Partners - Financial PR                    Tel: +44 (0)20 7457 2020

 Melanie Toyne-Sewell / Katie Duffell / Jack Kincade   OxfordBioDynamics@instinctif.com

 

Notes to Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing
personalized healthcare by developing and commercializing precision medicine
tests for life-changing diseases.

Its flagship products are the EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjphN2EwOmU5ZDc2NmYxZjYxNTk4OGE3YzY3NzkzYWRmODlmMmZmMzBmZmU2ZDZlZmNhMWI0ZmRlYjE3Nzc5N2Q4NmUzZTc6cDpU)
(Checkpoint Inhibitor Response Test) and EpiSwitch® PSE (EpiSwitch Prostate
Screening test) blood tests. CiRT is a predictive immune response profile for
immuno-oncology (IO) checkpoint inhibitor treatments, launched in February
2022. PSE is a blood test that boosts the predictive accuracy of a PSA test
from 55% to 94% when testing the presence or absence of prostate cancer, which
has been launched in the US via an early access program in September 2023;
launch in the UK will follow in Q4 2023.

The Company's first commercial prognostic test, EpiSwitch® CST
(https://url.avanan.click/v2/___https:/covidseveritytest.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjpmZWY1OmMzOGIyYTk2Yjk1OTgyMDNlMGFkNmQwZGU3ZmNmYzQwMzZmMGIwZDQ5NzA0OTAzNDc0NzY2ZDQyZGZiYjk5YWU6cDpU)
(Covid Severity Test), and the first commercially available microarray kit for
high-resolution 3D genome profiling and biomarker discovery, EpiSwitch®
Explorer Array Kit
(https://url.avanan.click/v2/___https:/store.oxfordbiodynamics.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjpiMWU2OjMzMTc0NWQ5ZWZhODg0MmY1N2EzZjY2YWRkZDI5YjBkOTRhM2M0ZTZkOGJkNWM2Y2I5MDE4MmQ4M2Y4ZjViMDY6cDpU)
, which is available for purchase by the life science research community, were
both launched in 2021.

The Company's product portfolio is based on a proprietary 3D genomic biomarker
platform, EpiSwitch®, which can build molecular diagnostic classifiers for
the prediction of response to therapy, patient prognosis, disease diagnosis
and subtyping, and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big
pharma and leading institutions including Pfizer, EMD Serono, Genentech,
Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi
Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker
arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an
expertly curated 3D genome knowledgebase comprising hundreds of millions of
data points from over 15,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock
Exchange. It also has a commercial office in Gaithersburg and a clinical
laboratory in Frederick, MD, USA, and a reference laboratory in Penang,
Malaysia.

For more information, please visit the Company's website,
www.oxfordbiodynamics.com
(https://url.avanan.click/v2/___http:/www.oxfordbiodynamics.com___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6Njo3ZjFmOjUxZjRiNmRmMzBiMGI3ZjA2NDJjNjFkZTc2MTM5MThjYjUxZGNiN2ZhNmRhNWRkMjY0MTAwNWY4ODA3ZjE4ZjU6cDpU)
, or follow OBD on Twitter
(https://url.avanan.click/v2/___https:/twitter.com/OxBioDynamics___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjplM2FmOjIwMTI1ZWNlOWJkYjRjZDQ1YjA4YWI2NDc0NWY1OWYzNzg1NTEzYjM0NjIwYTZmNTljNjk0YTQ1YzBkMjg0OTM6cDpU)
(@OxBioDynamics) and LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6Njo2YjgzOjcwMGI3YTM5ODdkMDVmNjA5ZDgxN2FmYWVjYTJkMjIzM2E3NTgzYzM0ZGIzMGIyZDIyYWZlZTVjN2QyZmY4ZGQ6cDpU)
.

About EpiSwitch®

The 3D configuration of the genome plays a crucial role in gene regulation. By
mapping this architecture and identifying abnormal configurations, EpiSwitch®
can be used to diagnose patients or determine how individuals might respond to
a disease or treatment.

Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics'
award-winning, proprietary platform that enables screening, evaluation,
validation and monitoring of 3D genomic biomarkers. The technology is fully
developed, based on testing of over 15,000 samples in 30 disease areas, and
reduced to practice.

In addition to stratifying patients with respect to anticipated clinical
outcomes, EpiSwitch® data offer insights into systems biology and the
physiological manifestation of disease that are beyond the scope of other
molecular modalities. The technology has performed well in academic medical
research settings and has been validated through its integration in biomarker
discovery and clinical development with big pharma.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABRGDSCUGDGSD